The state of Illinois currently has 8 active clinical trials seeking participants for COPD research studies. These trials are conducted in various cities, including Chicago, Peoria, Springfield and Urbana.
A Study to Investigate the Effect on Lung Function of an Approved COPD Treatment (BGF, With HFA Propellant) Compared to BGF Formulated With a New Propellant (HFO) in Participants 40 to 80 Years of Age With COPD
Recruiting
The purpose of this study is to demonstrate that the lung function effect from orally inhaled BGF delivered via HFO propellant is equivalent to the lung function effect from orally inhaled BGF delivered via HFA propellant in participants with COPD. The study duration for each participant will be approximately 15 to 16 weeks and consist of: A screening and placebo run-in period of approximately 2 weeks prior to first dosing Three treatment periods of approximately 4 weeks each (one period for ea... Read More
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
05/16/2024
Locations: Research Site, Chicago, Illinois
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab administered subcutaneously (SC) in adult participants with symptomatic COPD with a history of ≥ 2 moderate or ≥ 1 severe exacerbations of COPD in the 12 months prior to enrolment. Participants should be receiving optimised treatment with inhaled maintenance therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) throughout at least the last 3 months prior to enrolmen... Read More
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
05/07/2024
Locations: Research Site, Champaign, Illinois +2 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
The Reducing REVISITS Study: A Cluster RCT
Recruiting
This type II hybrid effectiveness-implementation trial will concurrently study the comparative effectiveness of virtual vs. in-person COPD care transition programs implemented via virtual mentored implementation approaches with and without co-design methods. The investigators will enroll up to 24 randomized sites (with a goal minimum of 16 sites) to: Deliver the COPD programs implemented via mentored support in collaboration with SHM Center for Quality Improvement. Compare the effectiveness an... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
05/06/2024
Locations: University of Chicago, Chicago, Illinois
Conditions: COPD, COPD Exacerbation Acute
A Study Comparing Efficacy, Safety and Tolerability of the Fixed Dose Triple Combination CHF 5993 With the Fixed Dose Dual Combination CHF 1535 in Subjects With COPD
Recruiting
The purpose of this study is to compare CHF 5993 with CHF 1535 in improving lung function, reducing moderate and severe COPD exacerbations, and other clinical efficacy and safety outcomes in the target subject population.
Gender:
All
Ages:
40 years and above
Trial Updated:
04/17/2024
Locations: Chiesi Clinical Trial Site 840365, Chicago Ridge, Illinois +1 locations
Conditions: COPD, COPD Exacerbation
SPIROMICS Study of Early COPD Progression (SOURCE)
Recruiting
This is an observational study of 1000 participants to further define the nature of early chronic obstructive pulmonary disease (COPD) in younger, at-risk individuals. The study has three main goals: To use CT scan imaging to identify which smokers will develop COPD. To identify biomarkers predictive of smokers that will develop COPD. To determine if sputum (phlegm) can be analyzed to predict which smokers will develop COPD. Procedures (methods): All participants will undergo study related qu... Read More
Gender:
All
Ages:
Between 30 years and 55 years
Trial Updated:
03/25/2024
Locations: University of Illinois Chicago, Chicago, Illinois
Conditions: COPD, Early-Onset
Long-term Efficacy and Safety of Tozorakimab in Participants With Chronic Obstructive Pulmonary Disease With a History of Exacerbations (PROSPERO).
Recruiting
Subjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with symptomatic COPD.
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
03/19/2024
Locations: Research Site, Evergreen Park, Illinois +1 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)
A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease
Recruiting
This study will evaluate the effect of triple ICS/LAMA/LABA therapy with BGF MDI 320/14.4/9.6 μg on cardiopulmonary outcomes relative to LAMA/LABA therapy with GFF MDI 14.4/9.6 μg in a population with COPD and elevated cardiopulmonary risk.
Gender:
All
Ages:
Between 40 years and 80 years
Trial Updated:
03/11/2024
Locations: Research Site, Chicago, Illinois +1 locations
Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Efficacy and Safety of Tozorakimab in Symptomatic Chronic Obstructive Pulmonary Disease With a History of Exacerbations
Recruiting
The purpose of this Phase III study is to evaluate the efficacy and safety of tozorakimab Dose 1 and Dose 2 administered subcutaneously (SC) in adult participants with symptomatic COPD and history of ≥ 2 moderate or ≥ 1 severe exacerbation of COPD in the previous 12 months. Participants should be receiving optimised treatment with maintenance inhaled therapy (ICS/LABA/LAMA triple therapy, or dual therapy if triple is not considered appropriate) in stable doses throughout at least 3 months prior... Read More
Gender:
All
Ages:
Between 40 years and 130 years
Trial Updated:
03/07/2024
Locations: Research Site, Chicago, Illinois +3 locations
Conditions: Chronic Obstructive Pulmonary Disease (COPD)